Fig. 3From: Cell-free osteochondral scaffolds provide a substantial clinical benefit in the treatment of osteochondral defects at a minimum follow-up of 5 yearsSubgroups analysis. Analysis of data depending on gender (Male/Female), age (< 35/> 35 years) and lesion etiology (Osteochondritis Dissecans/Osteonecrosis) for Subjective IKDC Score, Tegner-Lysholm score, VAS and Tegner Activity Level Scale (NS = not statistically significant)Back to article page